dipyridamole has been researched along with Huntington Disease in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Erythrocytes from patients with Huntington's disease showed no significant differences from erythrocytes of normal adults." | 1.26 | Lysophosphatidylcholine-induced lysis of erythrocytes in Duchenne and myotonic dystrophies and in Huntington's disease. ( Barr, AN; Danon, MJ; Lazowski, E; Omachi, A; Podolski, JL; Sarpel, G, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guitart, X | 1 |
| Chern, Y | 1 |
| Ferré, S | 1 |
| Omachi, A | 1 |
| Sarpel, G | 1 |
| Podolski, JL | 1 |
| Barr, AN | 1 |
| Lazowski, E | 1 |
| Danon, MJ | 1 |
2 other studies available for dipyridamole and Huntington Disease
| Article | Year |
|---|---|
Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease.
Topics: Age of Onset; Animals; Animals, Genetically Modified; Biomarkers; Brain; Carrier Proteins; Corpus St | 2017 |
Lysophosphatidylcholine-induced lysis of erythrocytes in Duchenne and myotonic dystrophies and in Huntington's disease.
Topics: Adult; Child; Dipyridamole; Dose-Response Relationship, Drug; Erythrocytes; Hemolysis; Humans; Hunti | 1982 |